We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nephron Gets 483 for Inadequate Sterility Testing of Asthma Drugs
Nephron Gets 483 for Inadequate Sterility Testing of Asthma Drugs
January 3, 2012
Nephron Pharmaceuticals may have inadvertently distributed batches of asthma medicine befouled by Bacillus bacteria, an FDA Form 483 states.